G1 Therapeutics, Inc.

NasdaqGS:GTHX Stock Report

Market Cap: US$378.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

G1 Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:GTHX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Jul 24SellUS$1,322John UmsteadIndividual527US$2.51
05 Jul 24SellUS$6,207Rajesh MalikIndividual2,475US$2.51
05 Jul 24SellUS$6,207Terry MurdockIndividual2,475US$2.51
05 Jul 24SellUS$19,214John BaileyIndividual7,662US$2.51
05 Jul 24SellUS$6,615Mark AvaglianoIndividual2,638US$2.51
05 Jul 24SellUS$3,353Andrew PerryIndividual1,337US$2.51
23 May 24SellUS$24,864Monica ThomasIndividual5,826US$4.27
13 May 24SellUS$178,421John BaileyIndividual37,258US$4.79
13 May 24SellUS$39,034Terry MurdockIndividual8,151US$4.79
13 May 24SellUS$39,034John UmsteadIndividual8,151US$4.79
13 May 24SellUS$39,034Andrew PerryIndividual8,151US$4.79
13 May 24SellUS$39,034Mark AvaglianoIndividual8,151US$4.79
13 May 24SellUS$39,034Rajesh MalikIndividual8,151US$4.79
18 Mar 24SellUS$19,752John UmsteadIndividual6,547US$3.02
04 Jan 24SellUS$327John UmsteadIndividual111US$2.94
04 Jan 24SellUS$2,121Terry MurdockIndividual721US$2.94
04 Jan 24SellUS$2,121Mark AvaglianoIndividual721US$2.94
04 Jan 24SellUS$2,121Rajesh MalikIndividual721US$2.94
03 Jan 24SellUS$36,447John BaileyIndividual11,686US$3.12
03 Jan 24SellUS$1,971John UmsteadIndividual632US$3.12
03 Jan 24SellUS$9,416Terry MurdockIndividual3,019US$3.12
03 Jan 24SellUS$10,480Mark AvaglianoIndividual3,360US$3.12
03 Jan 24SellUS$7,526Andrew PerryIndividual2,413US$3.12
03 Jan 24SellUS$9,416Rajesh MalikIndividual3,019US$3.12
02 Jan 24SellUS$108,006John BaileyIndividual32,983US$3.27

Insider Trading Volume

Insider Buying: GTHX insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of GTHX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,292,7782.44%
Hedge Funds5,179,5299.79%
VC/PE Firms7,166,70413.6%
General Public19,030,36936%
Institutions20,220,99538.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.

Top Shareholders

Top 25 shareholders own 56.42% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.79%
Beryl Capital Management LLC
5,179,529US$37.0m0%7.87%
7.97%
Eshelman Ventures, LLC
4,216,074US$30.1m0%100.0%
5.83%
BlackRock, Inc.
3,082,031US$22.0m359%no data
5.58%
MedImmune Ventures, Inc.
2,950,630US$21.1m0%100.0%
4.71%
The Vanguard Group, Inc.
2,491,109US$17.8m19.7%no data
2.58%
Woodline Partners LP
1,362,354US$9.7m0%0.09%
2.35%
Renaissance Technologies LLC
1,245,180US$8.9m37.8%0.01%
2.04%
Geode Capital Management, LLC
1,079,645US$7.7m113%no data
1.75%
Acadian Asset Management LLC
928,205US$6.6m114%0.02%
1.57%
State Street Global Advisors, Inc.
827,956US$5.9m414%no data
1.51%
Qube Research & Technologies Ltd
800,511US$5.7m147%0.01%
1.51%
Raymond James Financial Inc., Asset Management Arm
797,677US$5.7m-0.64%no data
1.45%
D. E. Shaw & Co., L.P.
767,066US$5.5m-2.32%0.01%
1.09%
Connor, Clark & Lunn Investment Management Ltd.
576,354US$4.1m39.4%0.02%
1.04%
Fredric Eshelman
550,000US$3.9m0%no data
0.88%
Jacobs Levy Equity Management Inc
463,593US$3.3m22.7%0.01%
0.8%
abrdn plc
423,869US$3.0m0%no data
0.75%
Bridgeway Capital Management, LLC
398,043US$2.8m108%0.05%
0.74%
Morgan Stanley, Investment Banking and Brokerage Investments
392,184US$2.8m124%no data
0.58%
Two Sigma Investments, LP
308,825US$2.2m-7.57%0.01%
0.4%
Two Sigma Advisers, LP
211,700US$1.5m15.2%no data
0.38%
Eversept Partners, L.P.
199,963US$1.4m0%0.1%
0.38%
Readystate Asset Management LP
199,358US$1.4m0%0.12%
0.37%
John Bailey
196,287US$1.4m4.35%no data
0.36%
STRS Ohio
192,700US$1.4m0%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/18 21:21
End of Day Share Price 2024/09/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

G1 Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harshita PolishettyB. Riley Securities, Inc.
Dane LeoneBTIG
Charles ButlerD. Boral Capital LLC.